Porton Advanced | ATMP CDMO/CRO

About Porton Advanced | ATMP CDMO/CRO

Porton Advanced is a Cell and Gene Therapy (CGT) CDMO/CRO. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization. Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 23 global IND approvals from NMPA, FDA, and Medsafe, with 8 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China. Porton Advanced is committed to a customer-centric approach, providing excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner. For more information about Porton Advanced, please visit: www.portonadvanced.com.